Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Stabilisation Notice

26 May 2021 09:24

RNS Number : 8745Z
Morgan Stanley & Co. Int'l plc
26 May 2021
 

26 May 2021

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

AstraZeneca PLC

Pre-stabilisation Period Announcement

Morgan Stanley & Co. International plc (contact: Morgan Stanley Debt Syndicate - Daniel Shane; telephone: +44 20 7677-7070) hereby gives notice, as Coordinating Stabilisation Manager, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 and the UK FCA Stabilisation Binding Technical Standards.

Securities

Issuer:

AstraZeneca PLC

Guarantor (if any):

N/A

Aggregate nominal amount:

TBC

Description:

EUR Fixed Rates Notes due 2029

Offer price:

TBC

Stabilisation

Stabilisation Manager(s):

Morgan Stanley & Co. International plc

Goldman Sachs International

J.P. Morgan Securities plc

Stabilisation period expected to start on:

26 May 2021

Stabilisation period expected to end no later than:

25 June 2021 (30 days after the proposed issue date of the securities)

Existence, maximum size and conditions of use of over-allotment facility:

The Stabilisation Manager(s) may over-allot the securities to the extent permitted in accordance with applicable laws and rules.

Stabilisation trading venue:

London Stock Exchange, Regulated Market

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities during the stabilisation period at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with Regulation (EU) 2017/1129 (the "EEA Prospectus Regulation") (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the EEA Prospectus Regulation), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the EEA Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, the UK before the publication of a prospectus in relation to the securities which has been approved by the competent authority in the UK in accordance with Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation"), this announcement and the offer are only addressed to and directed at persons in the UK who are qualified investors within the meaning of the UK Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in the UK.

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAAFMPTMTTTMTB
Date   Source Headline
1st Jun 20263:05 pmRNSAdmission of Further Securities to Trading
1st Jun 20263:00 pmRNSTotal Voting Rights
29th May 20267:00 amRNSImfinzi approved in US for early bladder cancer
27th May 20267:00 amRNSUS FDA decision date on camizestrant extended
26th May 20267:00 amRNSEnhertu recommended in EU for HER2+ solid tumours
26th May 20267:00 amRNSCamizestrant recommended for breast cancer in EU
26th May 20267:00 amRNSDatroway approved in US for 1L triple-negative BC
18th May 20263:00 pmRNSDirector/PDMR Shareholding
18th May 20267:05 amRNSEnhertu approved in two HER2+ early BC settings
18th May 20267:00 amRNSBaxfendy approved in the US for hypertension
14th May 20267:00 amRNSImfinzi + EV improves EFS & OS in bladder cancer
1st May 20263:00 pmRNSTotal Voting Rights and Admission of Shares
1st May 20267:05 amRNSFDA ODAC vote on camizestrant in breast cancer
1st May 20267:00 amRNSFDA ODAC recommends Truqap in prostate cancer
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20267:00 amRNSBreztri approved in the US for asthma
27th Apr 20267:00 amRNSSaphnelo self-administration approved in the US
23rd Apr 20267:00 amRNSDirectorate change
21st Apr 20267:00 amRNSI CAN PhIII interim analysis met primary endpoint
20th Apr 20267:00 amRNSThird tozorakimab positive Phase III in COPD
9th Apr 20265:15 pmRNSResult of AGM
2nd Apr 20267:00 amRNSImfinzi+Imjudo improves PFS in early liver cancer
1st Apr 20263:00 pmRNSTotal Voting Rights and Admission of Shares
31st Mar 20267:00 amRNSEfzimfotase alfa Ph3 program show positive results
27th Mar 20267:00 amRNSTozorakimab met OBERON/TITANIA primary endpoints
20th Mar 202611:00 amRNSNotification of Admission of Shares
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
10th Mar 202611:00 amRNSNotice of AGM
10th Mar 202611:00 amRNSNotice of AGM
6th Mar 202611:10 amRNSDirector/PDMR Shareholding
6th Mar 202611:05 amRNSDirector/PDMR Shareholding
6th Mar 202611:00 amRNSDirector/PDMR Shareholding
2nd Mar 20263:00 pmRNSTotal Voting Rights
26th Feb 20267:00 amRNSAstraZeneca prices a $2bn bond offering
25th Feb 20267:00 amRNSFiling of Form 20-F with SEC
24th Feb 202611:00 amRNSAnnual Financial Report
24th Feb 20267:00 amRNSDirectorate change
20th Feb 20267:00 amRNSFixed-duration Calquence combo approved in US
10th Feb 20267:00 amRNSFinal Results
3rd Feb 20267:00 amRNSUpdate on Saphnelo subcutaneous administration
2nd Feb 20263:00 pmRNSTotal Voting Rights
2nd Feb 20267:05 amRNSImfinzi recommended in EU for early gastric cancer
2nd Feb 20267:00 amRNSAstraZeneca begins trading on NYSE
30th Jan 20267:00 amRNSAstraZeneca agrees obesity and T2D deal with CSPC
29th Jan 20269:51 amRNSAstraZeneca invests $15bn in China through 2030
20th Jan 20267:00 amRNSAstraZeneca to complete direct listing on NYSE
8th Jan 20267:00 amRNSAZN new Head of Investor Relations Joris Silon
2nd Jan 20263:00 pmRNSTotal Voting Rights
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.